## Hydreight Launches NAD+ as Part of Robust Patient Service Offering

VANCOUVER, British Columbia and LAS VEGAS, Oct. 19, 2023 — Hydreight Technologies Inc. ("**Hydreight**" or the "**Company**") (TSXV:NURS)(OTCQB:HYDTF)(FSE:S06) a mobile clinical network and medical platform which enables flexible, at-home medical services across 50 states in the United States, is pleased to announce that it has launched NAD+ as part of its robust patient service offering on its proprietary healthcare technology platform.

NAD+ or *Nicotinamide Adenine Dinucleotide* is a coenzyme central to metabolism which is found in all living cells and consists of two nucleotides joined through their phosphate groups. Clinical studies have suggested that NAD+ may help to improve cognitive function, energy, weight management, pain management, and may also reduce and reverse effects of aging and more.

Hydreight is building the largest mobile clinical network in the United States for nurses to provide at- home healthcare services across 50 states. Currently, the Company platform offers various mobile services including: IV drip therapy, aesthetics, and now NAD+. The Company plans to continue adding products to its offering and will be launching lab testing and patient specific services in the next few months.

In order to start providing NAD+ services, Hydreight has customized its proprietary technology and updated the workflows across every state.

**Shane Madden, CEO of Hydreight** commented, "This is another significant milestone for the evolution and expansion of the Company. In terms of organic growth, we have recognized and are focused on three key areas: 1) increasing the number of nurses on our platform 2) increasing the products/services available to patients and 3) establishing white label partners that utilize our platform to reach more patients across the United States. Earlier in the year, we made some important investments into our proprietary technology which have paid off immensely. The advancements enable us to add new products and services, new locations, and update workflows smoothly and efficiently. Adding NAD+ to our at-home product portfolio provides medical professionals with additional health and wellness treatment options that may be accessed through the Hydreight platform. As we navigate the complex healthcare regulations across the United States, we will continue to look for opportunities to increase our value proposition and grow the business."

For more information on NAD+, please consult a healthcare professional.

## **About Hydreight Technologies Inc.**

Hydreight Technologies Inc. is building the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-

use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network that provides services in over 650 cities and growing.

On behalf of the Board of Directors

Shane Madden

Director and Chief Executive Officer

Hydreight Technologies Inc.

## Contact

Email: ir@hydreight.com; Telephone: (480) 790 6886

## **Cautionary Note Regarding Forward-Looking Information**

This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect", "Approximately" or similar expressions and includes information regarding the launch date of MedicalMedIV.com, and the anticipated effect on bookings and customer retention rates.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or predictions concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with

regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

